Inherited retinal dystrophy
MONDO:0019118An instance of retinal degeneration that is caused by an inherited modification of the individual's genome.
Also known as: fundus dystrophy, familial retinal dystrophy, genetic retinal dystrophy, hereditary retinal degeneration, hereditary retinal dystrophy, inherited retinal dystrophy, retinal dystrophy
521 clinical trials for this condition and its sub-types, 41 tagged with Inherited retinal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Inherited retinal dystrophy
-
Age-related macular degeneration 190 trials · 334 incl. sub-types
15 sub-types
- Wet macular degeneration 159 trials
- Dry age related macular degeneration 91 trials
- Age related macular degeneration 1 0 trials
- Age related macular degeneration 10 0 trials
- Age related macular degeneration 11 0 trials
- Age related macular degeneration 12 0 trials
- Age related macular degeneration 14 0 trials
- Age related macular degeneration 2 0 trials
- Age related macular degeneration 4 0 trials
- Age related macular degeneration 6 0 trials
- Age related macular degeneration 7 0 trials
- Age related macular degeneration 8 0 trials
- Age related macular degeneration 9 0 trials
- Macular degeneration, age-related, 3 0 trials
- Macular dystrophy with central cone involvement 0 trials
-
Retinitis pigmentosa 84 trials · 89 incl. sub-types
101 sub-types
- Retinitis pigmentosa 3 7 trials
- Retinitis pigmentosa 4 5 trials
- Retinitis pigmentosa 11 4 trials
- Retinitis pigmentosa 39 3 trials
- Retinitis pigmentosa 1 1 trial
- Retinitis pigmentosa 25 1 trial
- Retinitis pigmentosa 37 1 trial
- Retinitis pigmentosa 40 1 trial
- Retinitis pigmentosa 45 1 trial
- Retinitis pigmentosa 47 1 trial
- Retinitis pigmentosa Y-linked 1 trial
- Autosomal recessive pericentral pigmentary retinopathy 0 trials
- Cone-rod dystrophy 15 0 trials
- Cone-rod dystrophy 16 0 trials
- Cone-rod dystrophy 2 0 trials
- Dominant pericentral pigmentary retinopathy 0 trials
- Late-adult onset retinitis pigmentosa 0 trials
- Retinal dystrophy and obesity 0 trials
- Retinitis pigmentosa 10 0 trials
- Retinitis pigmentosa 100 0 trials
- Retinitis pigmentosa 12 0 trials
- Retinitis pigmentosa 13 0 trials
- Retinitis pigmentosa 14 0 trials
- Retinitis pigmentosa 17 0 trials
- Retinitis pigmentosa 18 0 trials
- Retinitis pigmentosa 19 0 trials
- Retinitis pigmentosa 2 0 trials
- Retinitis pigmentosa 20 0 trials
- Retinitis pigmentosa 22 0 trials
- Retinitis pigmentosa 23 0 trials
- Retinitis pigmentosa 24 0 trials
- Retinitis pigmentosa 26 0 trials
- Retinitis pigmentosa 27 0 trials
- Retinitis pigmentosa 28 0 trials
- Retinitis pigmentosa 29 0 trials
- Retinitis pigmentosa 30 0 trials
- Retinitis pigmentosa 31 0 trials
- Retinitis pigmentosa 32 0 trials
- Retinitis pigmentosa 33 0 trials
- Retinitis pigmentosa 34 0 trials
- Retinitis pigmentosa 35 0 trials
- Retinitis pigmentosa 36 0 trials
- Retinitis pigmentosa 38 0 trials
- Retinitis pigmentosa 41 0 trials
- Retinitis pigmentosa 42 0 trials
- Retinitis pigmentosa 43 0 trials
- Retinitis pigmentosa 44 0 trials
- Retinitis pigmentosa 46 0 trials
- Retinitis pigmentosa 48 0 trials
- Retinitis pigmentosa 49 0 trials
- Retinitis pigmentosa 50 0 trials
- Retinitis pigmentosa 51 0 trials
- Retinitis pigmentosa 53 0 trials
- Retinitis pigmentosa 54 0 trials
- Retinitis pigmentosa 55 0 trials
- Retinitis pigmentosa 56 0 trials
- Retinitis pigmentosa 57 0 trials
- Retinitis pigmentosa 58 0 trials
- Retinitis pigmentosa 59 0 trials
- Retinitis pigmentosa 6 0 trials
- Retinitis pigmentosa 60 0 trials
- Retinitis pigmentosa 61 0 trials
- Retinitis pigmentosa 62 0 trials
- Retinitis pigmentosa 63 0 trials
- Retinitis pigmentosa 64 0 trials
- Retinitis pigmentosa 65 0 trials
- Retinitis pigmentosa 66 0 trials
- Retinitis pigmentosa 67 0 trials
- Retinitis pigmentosa 68 0 trials
- Retinitis pigmentosa 69 0 trials
- Retinitis pigmentosa 7 0 trials
- Retinitis pigmentosa 7, digenic 0 trials
- Retinitis pigmentosa 70 0 trials
- Retinitis pigmentosa 71 0 trials
- Retinitis pigmentosa 72 0 trials
- Retinitis pigmentosa 73 0 trials
- Retinitis pigmentosa 74 0 trials
- Retinitis pigmentosa 75 0 trials
- Retinitis pigmentosa 76 0 trials
- Retinitis pigmentosa 77 0 trials
- Retinitis pigmentosa 78 0 trials
- Retinitis pigmentosa 79 0 trials
- Retinitis pigmentosa 80 0 trials
- Retinitis pigmentosa 81 0 trials
- Retinitis pigmentosa 83 0 trials
- Retinitis pigmentosa 84 0 trials
- Retinitis pigmentosa 85 0 trials
- Retinitis pigmentosa 86 0 trials
- Retinitis pigmentosa 87 with choroidal involvement 0 trials
- Retinitis pigmentosa 88 0 trials
- Retinitis pigmentosa 9 0 trials
- Retinitis pigmentosa 90 0 trials
- Retinitis pigmentosa 92 0 trials
- Retinitis pigmentosa 93 0 trials
- Retinitis pigmentosa 94, variable age at onset 0 trials
- Retinitis pigmentosa 95 0 trials
- Retinitis pigmentosa 96 0 trials
- Retinitis pigmentosa 97 0 trials
- Retinitis pigmentosa 98 0 trials
- Retinitis pigmentosa 99 0 trials
- Retinitis pigmentosa with or without situs inversus 0 trials
-
Hereditary macular dystrophy 3 trials · 70 incl. sub-types
17 sub-types
- Familial flecked retinopathy 0 trials · 43 incl. sub-types Sub-types →
- Macular corneal dystrophy 13 trials
- Vitelliform macular dystrophy 6 trials · 10 incl. sub-types Sub-types →
- Cone dystrophy 4 trials Sub-types →
- AICA-ribosiduria 1 trial
- Macular dystrophy, retinal 1 trial Sub-types →
- EEM syndrome 0 trials
- Benign concentric annular macular dystrophy 0 trials
- Coloboma of macula 0 trials
- Coloboma of macula-brachydactyly type B syndrome 0 trials
- Macular coloboma-cleft palate-hallux valgus syndrome 0 trials
- Macular dystrophy with or without cone dysfunction 0 trials
- Macular dystrophy, X-linked 0 trials
- Macular dystrophy, fenestrated sheen type 0 trials
- Occult macular dystrophy 0 trials
- Patterned dystrophy of the retinal pigment epithelium 0 trials Sub-types →
- Renal hypomagnesemia 5 with ocular involvement 0 trials
-
Cone-rod dystrophy 17 trials · 21 incl. sub-types
28 sub-types
- X-linked cone-rod dystrophy 0 trials · 2 incl. sub-types Sub-types →
- Cone-rod dystrophy 10 1 trial
- Cone-rod dystrophy 6 1 trial
- Leber congenital amaurosis 4 0 trials
- Newfoundland cone-rod dystrophy 0 trials
- Cone dystrophy 3 0 trials
- Cone-rod dystrophy 1 0 trials
- Cone-rod dystrophy 11 0 trials
- Cone-rod dystrophy 12 0 trials
- Cone-rod dystrophy 13 0 trials
- Cone-rod dystrophy 14 0 trials
- Cone-rod dystrophy 15 0 trials
- Cone-rod dystrophy 16 0 trials
- Cone-rod dystrophy 17 0 trials
- Cone-rod dystrophy 18 0 trials
- Cone-rod dystrophy 19 0 trials
- Cone-rod dystrophy 2 0 trials
- Cone-rod dystrophy 20 0 trials
- Cone-rod dystrophy 21 0 trials
- Cone-rod dystrophy 22 0 trials
- Cone-rod dystrophy 24 0 trials
- Cone-rod dystrophy 3 0 trials
- Cone-rod dystrophy 5 0 trials
- Cone-rod dystrophy 7 0 trials
- Cone-rod dystrophy 8 0 trials
- Cone-rod dystrophy 9 0 trials
- Macular degeneration, X-linked atrophic 0 trials
- Retinal cone dystrophy 4 0 trials
-
Leber congenital amaurosis 10 trials · 12 incl. sub-types
21 sub-types
- Leber congenital amaurosis 10 2 trials
- Leber congenital amaurosis 2 2 trials
- Leber congenital amaurosis 5 2 trials
- Leber congenital amaurosis 1 1 trial
- Leber congenital amaurosis 11 0 trials
- Leber congenital amaurosis 12 0 trials
- Leber congenital amaurosis 13 0 trials
- Leber congenital amaurosis 14 0 trials
- Leber congenital amaurosis 15 0 trials
- Leber congenital amaurosis 16 0 trials
- Leber congenital amaurosis 17 0 trials
- Leber congenital amaurosis 18 0 trials
- Leber congenital amaurosis 19 0 trials
- Leber congenital amaurosis 3 0 trials
- Leber congenital amaurosis 4 0 trials
- Leber congenital amaurosis 6 0 trials
- Leber congenital amaurosis 7 0 trials
- Leber congenital amaurosis 8 0 trials
- Leber congenital amaurosis 9 0 trials
- Leber congenital amaurosis with early-onset deafness 0 trials
- Retinal aplasia 0 trials
-
ABCA4-related retinopathy 7 trials · 11 incl. sub-types
3 sub-types
- Severe early-childhood-onset retinal dystrophy 8 trials
- Cone-rod dystrophy 3 0 trials
- Retinitis pigmentosa 19 0 trials
-
RPE65-related recessive retinopathy 5 trials · 7 incl. sub-types
2 sub-types
- Leber congenital amaurosis 2 2 trials
- Retinitis pigmentosa 20 0 trials
-
BEST1-related dominant retinopathy 1 trial · 7 incl. sub-types
1 sub-type
- Vitelliform macular dystrophy 2 7 trials
-
RHO-related retinopathy 0 trials · 7 incl. sub-types
2 sub-types
-
RPGR-related retinopathy 0 trials · 7 incl. sub-types
3 sub-types
- Retinitis pigmentosa 3 7 trials
- X-linked cone-rod dystrophy 1 0 trials
- Macular degeneration, X-linked atrophic 0 trials
-
Choroideremia 6 trials
2 sub-types
- Choroideremia hypopituitarism 0 trials
- Total central choroidal atrophy 0 trials
-
X-linked retinoschisis 4 trials
-
PRPF31-related retinopathy 1 trial · 4 incl. sub-types
1 sub-type
- Retinitis pigmentosa 11 4 trials
-
RLBP1-related retinopathy 2 trials · 3 incl. sub-types
3 sub-types
- Fundus albipunctatus 1 trial Sub-types →
- Bothnia retinal dystrophy 0 trials
- Newfoundland cone-rod dystrophy 0 trials
-
ELOVL4-related maculopathy 0 trials · 3 incl. sub-types
1 sub-type
- Stargardt disease 3 3 trials
-
Revesz syndrome 2 trials
-
Late-onset retinal degeneration 2 trials
-
EYS-related retinopathy 1 trial · 2 incl. sub-types
1 sub-type
- Retinitis pigmentosa 25 1 trial
-
LCA5-related retinopathy 1 trial · 2 incl. sub-types
1 sub-type
- Leber congenital amaurosis 5 2 trials
-
PRPH2-related retinopathy 1 trial · 2 incl. sub-types
7 sub-types
- Fundus albipunctatus 1 trial Sub-types →
- Leber congenital amaurosis 18 0 trials
- Choroidal dystrophy, central areolar 2 0 trials
- Patterned macular dystrophy 1 0 trials
- Retinitis pigmentosa 7 0 trials
- Retinitis pigmentosa 7, digenic 0 trials
- Vitelliform macular dystrophy 3 0 trials
-
BEST1-related recessive retinopathy 0 trials · 2 incl. sub-types
1 sub-type
- Autosomal recessive bestrophinopathy 2 trials
-
AIPL1-related retinopathy 1 trial
1 sub-type
- Leber congenital amaurosis 4 0 trials
-
Retinoschisis of fovea 1 trial
-
ATF6-related retinopathy 0 trials · 1 incl. sub-types
1 sub-type
- Achromatopsia 7 1 trial
-
CNGB1-related retinopathy 0 trials · 1 incl. sub-types
1 sub-type
- Retinitis pigmentosa 45 1 trial
-
FLVCR1-related retinopathy with or without ataxia 0 trials · 1 incl. sub-types
1 sub-type
-
GUCY2D retinopathy 0 trials · 1 incl. sub-types
3 sub-types
- GUCY2D-related recessive retinopathy 0 trials · 1 incl. sub-types Sub-types →
- Cone-rod dystrophy 6 1 trial
- GUCY2D-related dominant retinopathy 0 trials Sub-types →
-
RDH5-related retinopathy 0 trials · 1 incl. sub-types
1 sub-type
- Fundus albipunctatus 1 trial Sub-types →
-
ADAM9-related retinopathy 0 trials
1 sub-type
- Cone-rod dystrophy 9 0 trials
-
CACNA1F-related retinopathy 0 trials
3 sub-types
- Aland island eye disease 0 trials
- X-linked cone-rod dystrophy 3 0 trials
- Congenital stationary night blindness 2A 0 trials
-
CACNA2D4-related retinopathy 0 trials
1 sub-type
- Retinal cone dystrophy 4 0 trials
-
CDHR1-related retinopathy 0 trials
3 sub-types
- Cone-rod dystrophy 15 0 trials
- Macular dystrophy, retinal, 5 0 trials
- Retinitis pigmentosa 65 0 trials
-
CERKL-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 26 0 trials
-
CNGA1-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 49 0 trials
-
CNGA3-related retinopathy 0 trials
1 sub-type
- Achromatopsia 2 0 trials
-
CRX-related retinopathy 0 trials
2 sub-types
- Leber congenital amaurosis 7 0 trials
- Cone-rod dystrophy 2 0 trials
-
GNAT2-related retinopathy 0 trials
1 sub-type
- Achromatopsia 4 0 trials
-
GPR179-related retinopathy 0 trials
1 sub-type
-
GRM6-related retinopathy 0 trials
1 sub-type
-
GUCA1A-related retinopathy 0 trials
2 sub-types
- Cone dystrophy 3 0 trials
- Cone-rod dystrophy 14 0 trials
-
HGSNAT-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 73 0 trials
-
IDH3B-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 46 0 trials
-
IMPDH1-related retinopathy 0 trials
2 sub-types
- Leber congenital amaurosis 11 0 trials
- Retinitis pigmentosa 10 0 trials
-
IMPG1-related dominant retinopathy 0 trials
1 sub-type
-
IMPG1-related recessive retinopathy 0 trials
1 sub-type
- Vitelliform macular dystrophy 4 0 trials
-
IMPG2-related dominant retinopathy 0 trials
1 sub-type
- Vitelliform macular dystrophy 5 0 trials
-
IMPG2-related recessive retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 56 0 trials
-
KCNV2-related retinopathy 0 trials
1 sub-type
-
KIZ-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 69 0 trials
-
LRIT3-related retinopathy 0 trials
1 sub-type
-
MAK-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 62 0 trials
-
MERTK-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 38 0 trials
-
MRCS syndrome 0 trials
-
NMNAT1-related retinopathy 0 trials
-
NYX-related retinopathy 0 trials
1 sub-type
-
Oguchi disease 0 trials
2 sub-types
- Oguchi disease-1 0 trials
- Oguchi disease-2 0 trials
-
PCARE-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 54 0 trials
-
PDE6A-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 43 0 trials
-
PDE6C-related retinopathy 0 trials
1 sub-type
- Cone dystrophy 4 0 trials Sub-types →
-
PDE6G-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 57 0 trials
-
PROM1-related retinopathy 0 trials
3 sub-types
- PROM1-related dominant retinopathy 0 trials Sub-types →
- PROM1-related recessive retinopathy 0 trials Sub-types →
- Cone-rod dystrophy 12 0 trials
-
PRPF8-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 13 0 trials
-
RAB28-related retinopathy 0 trials
1 sub-type
- Cone-rod dystrophy 18 0 trials
-
RD3-related retinopathy 0 trials
1 sub-type
- Leber congenital amaurosis 12 0 trials
-
RDH12-related dominant retinopathy 0 trials
-
RDH12-related recessive retinopathy 0 trials
1 sub-type
- Leber congenital amaurosis 13 0 trials
-
REEP6-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 77 0 trials
-
RP1-related dominant retinopathy 0 trials
-
RP1-related recessive retinopathy 0 trials
-
RP2-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 2 0 trials
-
RPE65-related dominant retinopathy 0 trials
1 sub-type
-
1 sub-type
- Retinitis pigmentosa 33 0 trials
-
SPATA7-related retinopathy 0 trials
2 sub-types
- Leber congenital amaurosis 3 0 trials
- Retinitis pigmentosa 94, variable age at onset 0 trials
-
Sorsby fundus dystrophy 0 trials
1 sub-type
-
TOPORS-related retinopathy 0 trials
1 sub-type
- Retinitis pigmentosa 31 0 trials
-
TRPM1-related retinopathy 0 trials
1 sub-type
-
TTLL5-related retinopathy 0 trials
1 sub-type
- Cone-rod dystrophy 19 0 trials
-
X-linked retinal dysplasia 0 trials
-
Aceruloplasminemia 0 trials
-
Amaurosis-hypertrichosis syndrome 0 trials
-
Familial benign flecked retina 0 trials
-
Macular degeneration, early-onset 0 trials
-
Microcephaly and chorioretinopathy 1 0 trials
-
Oligocone trichromacy 0 trials
-
1 sub-type
- Basal laminar drusen 0 trials
-
Retinoschisis, autosomal dominant 0 trials
-
Vitreoretinal dystrophy 0 trials
Most studied deeper sub-types
-
Could a daily eye gel replace injections for wet AMD?
Disease control Not yet recruitingThis trial is testing an experimental eye gel called BETA-TT8 for people with wet age-related macular degeneration (AMD), a condition that causes rapid vision loss. The gel is applied to the eye up to three times daily for 12 weeks, and standard injections remain available if nee…
Phase 1/2 • Sponsor: Filamon LTD • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
One eye injection, four targets: GenSci148 tested against retinal swelling
Disease control Not yet recruitingResearchers are testing an experimental eye injection called GenSci148 in people with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). GenSci148 is a fusion protein designed to block four proteins involved in blo…
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New eye drug goes Head-to-Head with standard treatment for wet AMD
Disease control Not yet recruitingResearchers are testing an experimental drug called OLN324 against ranibizumab, a standard treatment for wet age-related macular degeneration (nAMD). The trial enrolls about 400 adults aged 50 and older who have not yet received treatment for active wet AMD in the study eye. Part…
Phase 3 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New eye drug goes Head-to-Head with standard care for wet AMD
Disease control Not yet recruitingResearchers are testing an experimental drug called OLN324 against the standard treatment, aflibercept, in adults with wet age-related macular degeneration. About 500 people aged 50 and older who have not yet received treatment for this condition will take part. Both drugs are gi…
Phase 3 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new eye injection beat the standard for wet AMD?
Disease control Not yet recruitingThis trial tests an experimental drug called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Researchers compare two doses of VIS-101 against aflibercept, a standard treatment, to see if VIS-…
Phase 2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new eye injection protect vision in geographic atrophy?
Disease control Not yet recruitingThis study tests the long-term safety of vonaprument, an experimental drug given as an injection into the eye, for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. Researchers will monitor participants who completed an…
Phase 3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a light beam slow vision loss? new trial tests laser therapy for AMD
Disease control Not yet recruitingThis study tests a non-invasive laser treatment called photobiomodulation for people with early age-related macular degeneration (AMD) who have a specific type of deposit in the eye called reticular pseudodrusen. The treatment uses low-energy light to stimulate cells and reduce i…
Sponsor: Fondazione G.B. Bietti, IRCCS • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can an eye injection slow a genetic cause of blindness?
Disease control Not yet recruitingThis trial tests the long-term safety of an experimental medicine called ultevursen, given as an injection into the eye, for people with retinitis pigmentosa caused by mutations in a gene called USH2A. The study enrolls about 81 adults and children who completed a previous 24-mon…
Phase 2 • Sponsor: Laboratoires Thea • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
One-Time gene injection aims to halt rare blindness
Disease control Not yet recruitingThis trial tests a single injection of a gene therapy called ZVS101e for people with Bietti crystalline dystrophy, a rare inherited eye disease that leads to progressive vision loss. The therapy uses a harmless virus to deliver a working copy of the CYP4V2 gene to cells in the ey…
Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a statin nanoparticle save sight in retinitis pigmentosa?
Disease control Not yet recruitingThis phase 1 trial tests whether an intravenous nanoparticle formulation of pitavastatin, called ULREA-PVS-NP, is safe in adults with retinitis pigmentosa, a rare inherited disease that causes progressive vision loss. The study aims to see if the treatment can reduce retinal infl…
Phase 1 • Sponsor: Kyushu University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Laser zap before eye injection could cut needle count for wet AMD
Disease control Not yet recruitingThis study tests whether a low-intensity laser applied to the diseased area just before an anti-VEGF injection helps the drug work better in people with wet age-related macular degeneration (AMD). Wet AMD causes abnormal blood vessels to leak fluid under the retina, and current t…
Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Longer-Lasting eye injection could cut treatment visits for macular disease
Disease control Not yet recruitingThis study looks at whether switching to a higher-dose eye injection called aflibercept 8 mg can allow people with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DME) to go longer between treatments. It follows adults in Portugal who have already …
Sponsor: Grupo de Estudos da Retina • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Gene therapy injection aims to halt blinding eye disease
Disease control Not yet recruitingThis early-stage trial tests a gene therapy called AGX-08 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. The study will involve 24 people aged 50 and older, each receiving a single injection into one eye. The main goal is to …
Early phase 1 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a higher dose of an existing eye drug cut injection frequency for wet AMD?
Disease control Not yet recruitingThis trial is investigating whether a higher 8 mg dose of aflibercept, given every three months, can effectively control wet age-related macular degeneration (nAMD) in people who have not been treated before. The study will measure changes in eye fluid biomarkers, vision, and saf…
Early phase 1 • Sponsor: Tianjin Medical University Eye Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can an antioxidant pill slow blindness in usher syndrome?
Disease control Not yet recruitingThis phase 3 trial tests whether an experimental drug called NPI-001 can slow the loss of light-sensing cells in the eyes of adults with Usher syndrome, a genetic condition that causes both hearing and vision loss. About 80 participants take either NPI-001 or a placebo twice dail…
Phase 3 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Gene therapy injection aims to halt blinding eye disease
Disease control Not yet recruitingThis trial tests a gene therapy called PST-611 in people aged 65 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. PST-611 is a DNA plasmid injected into the eye muscle that instructs cells to produce human transferri…
Phase 2 • Sponsor: Eyevensys • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
One-Time gene injection aims to rescue sight in rare childhood blindness
Disease control Not yet recruitingThis study tests a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare condition that leads to severe vision loss from a young age. The treatment is given as a single injection under the retina in the worse…
Phase 1/2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a daily electric zap to the eye preserve sight in dry AMD?
Disease control Not yet recruitingThis trial investigates whether a personal-use electric stimulator, worn at home for 30 minutes daily, can improve vision in people with early to intermediate dry age-related macular degeneration (AMD). Participants are randomly assigned to receive either real or sham stimulation…
Sponsor: Nu Eyne Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug aims to preserve sight in rare genetic blindness
Disease control Not yet recruitingThis phase 3 trial tests whether NPI-001, taken twice daily for 24 months, can slow the loss of light-sensing cells in the eyes of adults with Usher syndrome, a genetic condition that causes both hearing and vision loss. About 80 participants will receive either the drug or a pla…
Phase 3 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill aims to slow vision loss from dry macular degeneration
Disease control Not yet recruitingThis study tests an oral drug called STL303 for geographic atrophy, a form of dry age-related macular degeneration that causes a blind spot in central vision. About 300 adults aged 60 and older will receive either STL303 or a placebo pill for up to 2 years. The goal is to see if …
Phase 2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Dietary intervention aims to slow macular degeneration progression
Disease control Not yet recruitingThis study tests whether a remote dietary program can help people with early to intermediate age-related macular degeneration (AMD) lower their blood sugar and increase protective nutrients called carotenoids. About 32 participants will receive coaching to improve their eating ha…
Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Eye drops could replace needle injections for wet AMD
Disease control Not yet recruitingThis Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…
Phase 2 • Sponsor: SCAI Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy takes on rare eye disease in Second-Eye trial
Disease control Not yet recruitingThis study is for people with Bietti's crystalline dystrophy, a rare genetic eye disease that causes vision loss. They have already received the gene therapy VGR-R01 in one eye. Now, researchers want to test if giving the same treatment to the other eye is safe and can improve vi…
Phase 1/2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New eye drug faricimab tested for blinding disease
Disease control Not yet recruitingThis study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, me…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Smartphone app could help wet AMD patients space out eye injections
Disease control Not yet recruitingThis study looks at whether a home monitoring app can help people with wet age-related macular degeneration (eAMD) safely extend the time between Aflibercept injections. About 80 adults already receiving this treatment will use the app and have regular eye exams over one to two y…
Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could zapping a nerve in your face save your sight?
Disease control Not yet recruitingThis early study tests whether stimulating a nerve cluster behind the cheekbone (the pterygopalatine ganglion) is safe and doable for people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots. Sixty-two adults will receive either re…
Sponsor: Shanghai Institute of Acupuncture, Moxibustion and Meridian • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New eye injection could mean fewer doctor visits for wet AMD patients
Disease control Not yet recruitingThis study tests a new medicine called AIV007 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce t…
Phase 2 • Sponsor: AiViva BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New eye drug aims to block two causes of vision loss at once
Disease control Not yet recruitingThis study tests an investigational drug called OCUL101 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision and can lead to blindness. OCUL101 targets two proteins involved in the disease to reduce abnormal blood vessel growth and inf…
Phase 2/3 • Sponsor: Shenzhen Oculgen Biomedical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene therapy injection aims to save sight in rare eye disease
Disease control Not yet recruitingThis early-stage trial tests a single injection of ZM-02, a gene therapy, in 21 people aged 6 to 60 with advanced retinitis pigmentosa, a genetic condition that causes progressive vision loss. Participants are randomly assigned to receive either a low or high dose of ZM-02 or a s…
Phase 1/2 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could herbal pills cut eye injections for wet AMD? new trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will …
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug, QL1207H, works as well as the standard treatment Eylea for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, …
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Stem cell therapy for rare eye disease passes 5-year safety check
Disease control Not yet recruitingThis study follows up 18 people who received umbilical cord stem cells or conditioned medium for retinitis pigmentosa, a rare eye disease that causes vision loss. Researchers will check vision, eye structure, and safety five years after the injection. The goal is to see if the tr…
Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could stem cells save sight? new trial tests umbilical cord therapy for eye disease
Disease control Not yet recruitingThis study tests whether stem cells from umbilical cord tissue can safely slow vision loss in people with retinitis pigmentosa, an inherited eye disease. Thirty participants will receive one of two doses injected around the eye and be monitored for six months. The main goals are …
Phase 2/3 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Lab-Grown eye cells implanted to fight blindness
Disease control Not yet recruitingThis early-stage trial tests whether transplanting lab-grown retinal cells (made from stem cells) into the eye is safe for people with late-stage age-related macular degeneration. Nine participants will receive the cell transplant and be monitored for side effects and any improve…
Phase 1/2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New eye drug GB10 enters early human testing for wet AMD
Disease control Not yet recruitingThis early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know i…
Phase 1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can red light slow vision loss in dry AMD?
Disease control Not yet recruitingThis study tests a new, non-invasive treatment for dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. About 94 people aged 50 and older with dry AMD will use a red-light device at home twice daily for three months. Researchers will check if…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a bladder pill save your sight? new trial tests mirabegron for dry AMD
Disease control Not yet recruitingThis study tests whether mirabegron, a drug used for overactive bladder, can help people with dry age-related macular degeneration (AMD). Researchers will give 312 patients aged 50-80 either mirabegron or a standard bladder drug for 12 months and check for changes in the retina. …
Sponsor: University of Naples • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for PCV: higher-dose eye injection may reduce treatment burden
Disease control Not yet recruitingThis study tests a stronger dose (8 mg) of the drug aflibercept in Chinese patients with polypoidal choroidal vasculopathy (PCV), a type of wet age-related macular degeneration that can cause rapid vision loss. About 174 people who have not been treated before will receive three …
Phase 4 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Gene therapy injection aims to slow vision loss in rare eye disease
Disease control Not yet recruitingThis early-stage trial tests a single injection of a gene therapy drug called UGX202 in 6 adults with advanced retinitis pigmentosa, a genetic condition that causes vision loss. The main goal is to check if the treatment is safe and tolerable over 52 weeks. Researchers will also …
Early phase 1 • Sponsor: Suzhou UgeneX Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill aims to slow vision loss in dry AMD
Disease control Not yet recruitingThis study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The …
Phase 2 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could pond scum help teens see better? new trial tests alga extract for rare eye disease
Disease control Not yet recruitingThis study tests whether a powder made from a special alga can help preserve or improve vision in teenagers with retinitis pigmentosa, a genetic eye disease that causes vision loss. Thirty participants aged 12-18 will take the alga extract daily for one year. The study will measu…
Phase 1/2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New eye drug trial aims to save sight in Hard-to-Treat AMD
Disease control Not yet recruitingThis study tests faricimab, a drug injected into the eye, for people with type 3 wet age-related macular degeneration (AMD), a condition that can cause rapid vision loss. Over 76 weeks, 30 participants will receive initial monthly doses, then a personalized schedule where injecti…
Phase 4 • Sponsor: Kim's Eye Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
One-Shot gene therapy aims to end monthly eye injections for wet AMD
Disease control Not yet recruitingThis early-stage trial tests EXG202, a gene therapy given as a single injection into the eye for people with wet age-related macular degeneration (AMD). The goal is to see if it is safe and can produce a protein that blocks abnormal blood vessel growth long-term, potentially redu…
Phase 1/2 • Sponsor: Guangzhou Jiayin Biotech Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
AI assistant could sharpen eye injection choices
Diagnosis Not yet recruitingThis trial tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet AMD, DME, and RVO. About 200 patients who have completed initial treatment will be randomly assigned to have their doctor use …
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New eye camera could diagnose problems in seconds
Diagnosis Not yet recruitingThis study tests a compact, handheld eye imaging device that takes pictures of the eye in seconds. Researchers want to see if it is easy to use, mobile, and reliable. The device will be tested on 70 people with eye complaints, and the images will be compared to official diagnoses…
Sponsor: Duke University • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
New eye scanner could spot hidden signs of blindness
Diagnosis Not yet recruitingThis study will test a new, non-invasive eye scanner called wide field OCTA in 200 people with various eye diseases, including age-related macular degeneration, diabetic retinopathy, and dry eye. The goal is to see if this device can provide better images of blood vessels in the …
Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
AI eye doctor: new study aims to spot Blindness-Causing diseases faster
Diagnosis Not yet recruitingThis study will test a new artificial intelligence (AI) system that reads eye scans (OCT) to diagnose common blinding eye diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration. Researchers will collect 2000 eye scans from patients at Peking Union Medi…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Could a cotton swab replace the metal speculum for eye injections?
Symptom relief Not yet recruitingThis study tests if using a cotton-tipped applicator to hold the eyelid open during eye injections is less painful and faster than the standard metal speculum. About 120 adults with certain eye conditions will take part. The goal is to improve comfort and satisfaction without com…
Sponsor: Jakkrit Juhong • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Meditation or health classes may ease burden of vision loss
Symptom relief Not yet recruitingThis study tests whether meditation or a health education program can improve quality of life and mental health for people with irreversible age-related vision loss and their caregivers. About 150 participants will be assigned to either meditation training or health classes, both…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Sound waves to restore sight? new ultrasound trial for AMD and RP patients
Symptom relief Not yet recruitingThis early study tests whether a wearable ultrasound device can safely stimulate retinal cells and help restore vision in people with age-related macular degeneration or retinitis pigmentosa. Five participants will receive short ultrasound pulses while reporting what they see. Th…
Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
AI glasses could help blind people navigate the world
Symptom relief Not yet recruitingThis study tests whether Meta AI glasses, connected to the Be My Eyes network, can help people with permanent vision loss walk and move around more easily. The glasses describe scenes and objects in real time. Fifty participants will use the glasses and report changes in their qu…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Smart contact lens could help those with vision loss see better
Symptom relief Not yet recruitingThis study tests a miniaturized smart contact lens in 32 people—some healthy, some with Stargardt's disease—to see if it is comfortable and easy to use. The lens tracks eye movements to help with vision tasks. Researchers will check for side effects and ask participants how they …
Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts • Aim: Symptom relief
Last updated Jun 26, 2026 18:34 UTC
-
The 20-Minute squeeze: how eye injections push pressure up
Knowledge-focused Not yet recruitingAnti-VEGF injections treat conditions like diabetic macular edema, age-related macular degeneration, and retinal vein occlusion by adding fluid inside the eye, which can briefly raise eye pressure. This observational study at Assiut University follows 50 adults receiving these ro…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could years of eye injections weigh down the upper eyelid?
Knowledge-focused Not yet recruitingDoctors use anti-VEGF injections to treat retinal diseases such as age-related macular degeneration and diabetic macular edema, and patients often need these shots for years. During each injection, a small tool holds the eyelids open, stretching the upper lid. Researchers want to…
Sponsor: Abdulkadir Küçük • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Could eye drops replace injections for a leading cause of blindness?
Knowledge-focused Not yet recruitingThis early-stage trial is evaluating the safety, tolerability, and how the body absorbs PAN-90806, an experimental eye drop being developed for wet age-related macular degeneration (AMD), a leading cause of vision loss. Healthy adults aged 18 to 50 will receive either PAN-90806 o…
Phase 1 • Sponsor: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
A sharper look at the retina: new imaging technology may spot eye disease earlier
Knowledge-focused Not yet recruitingThis study is testing whether a specialized eye scanner called the MONA IV can capture clear, detailed images of the retina's tiny cells and blood vessels. Researchers will use it in people with conditions like glaucoma or age-related macular degeneration, as well as in healthy v…
Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Blindness may boost your sense of taste and smell, scientists say
Knowledge-focused Not yet recruitingThis study investigates whether people with central or peripheral vision loss develop heightened senses of taste and smell. Researchers will measure brain responses to sweet and vanilla flavors in 50 visually impaired adults and compare them to sighted controls. The goal is to un…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Veterans with vision loss may get new rehab tools
Knowledge-focused Not yet recruitingThis study aims to develop new methods to help veterans with vision loss caused by age-related macular degeneration. About 20 veterans aged 50 and older with reduced vision will take part. Researchers will measure how well they recognize objects and how their brains respond befor…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New eye camera could spot retinal disease earlier
Knowledge-focused Not yet recruitingThis study will test a new, noninvasive camera called XyCAM CRE that measures blood flow in the back of the eye. Researchers will compare its images with standard eye tests in 350 adults with retinal disorders. The goal is to see if this camera can provide extra information to he…
Sponsor: Stuart Terry Eye Associates • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study aims to keep macular disease patients on track with eye injections
Knowledge-focused Not yet recruitingThis study tests whether a personalized care approach helps patients with chronic macular diseases (like wet age-related macular degeneration and diabetic macular edema) attend their regular eye injection appointments. Many patients skip these vital treatments, risking further vi…
Sponsor: Singapore Eye Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Teen depression study tracks heartbeats and family bonds
Knowledge-focused Not yet recruitingThis study looks at how heart rate variability (a measure of stress response) relates to emotional control and parent-teen relationships in 74 adolescents with depression. Teens will wear a Fitbit while sleeping for a week and fill out questionnaires. The goal is to better unders…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI vs. human eye: study tests if smart software improves retinal reports
Knowledge-focused Not yet recruitingThis study looks at whether giving eye doctors AI-generated measurements from retinal images helps them write more accurate and complete reports. About 29 ophthalmologists and trainees will be randomly assigned to use AI tools or just the original images. A panel of senior expert…
Sponsor: Beijing Tongren Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Virtual reality could revolutionize how we measure vision loss
Knowledge-focused Not yet recruitingThis study aims to see if virtual reality tests can better measure how age-related macular degeneration affects daily life compared to standard eye exams. Researchers will enroll 60 participants, including healthy adults and those with the eye condition. The goal is to develop a …
Sponsor: Streetlab • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Elderly AMD patients to test Easy-to-Use home vision tracker
Knowledge-focused Not yet recruitingThis study aims to see if elderly patients with age-related macular degeneration (AMD) find a new web-based eye-tracking system easy and acceptable to use at home. The system is designed to help patients monitor their vision without frequent clinic visits. Thirty patients aged 55…
Sponsor: Tan Tock Seng Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists track eye disease patterns to speed future cures
Knowledge-focused Not yet recruitingThis study looks back at medical records of 200 people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Researchers will analyze vision tests and eye scans to see how these diseases progress and how genetics affect symptoms. The goal is to find be…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
New study aims to link eye scans with vision loss in macular dystrophy
Knowledge-focused Not yet recruitingThis study will look at 30 people with macular dystrophy to see how different eye tests—like OCT scans, mfERG, and standard vision tests—relate to each other. The goal is to better understand how these tests can track vision changes. No treatment is being tested; this is purely a…
Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:22 UTC